DOCSLIB.ORG

MASENZ DANYA GROUP SL, Is an EUROPEAN Pharmaceutical Company Based in BARCELONA, Spain

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
MASENZ DANYA GROUP SL, Is an EUROPEAN Pharmaceutical Company Based in BARCELONA, Spain CATALOGUE ABOUT US MASENZ DANYA GROUP SL, is an EUROPEAN pharmaceutical company based in BARCELONA, Spain. Specializing in research, sourcing and distribution of raw materials, MASENZ DANYA GROUP SL is progressing serenely each year through distribution agreements signed with companies around the world; concerned about the quality of our products and our organization, MASENZ has consolidated a strong EUROPEAN market position. We are now developing at the international and thus carry more than 40% of our turnover from exports to over 30 countries in Europe, Asia, Africa and America. We meet the specific demands of our customers by seeking new products and new suppliers worldwide. Masenz Danya Group SL +34 933 484 605 Narcís Monturiol 37, 08960 Barcelona, www.masenzgroup.com 2 Ciprofloxacin CEP API Citalopram Citicoline Clarithromycin Clindamycin Palmitate G Clomifene Gabapentin Clonazepam Gentamycine CEP A Clonidine Glibenclamide Acetazolamide Clopidogrel bisulphate Gliclazide Acyclovir CEP Clozapine Glimepiride Adrenaline Colchicine Glipizide Alendronate Sodium Cobalamine Glucosamine Sulphate Ambroxol CEP Cyproheptadine Guaifenesin Amlodipine Besylate CEP D H Alprazolam Desloratadine CEP Haloperidol Aluminium Hydroxide- Magnesium Desmopressin Acetate Hydrochlorothiazide CEP Amiodarone Hcl Dexchlorpheniramine Maleate Hydroxyzine Hcl Amitriptylline Hcl Dexlansoprazole Hydroxocobalamine Amoxicilline CEP Dextrometorphane I Aripiprazole CEP Diclofenac Ibuprofen CEP Atenolol Diltiazem Imipenem Atorvastatin Digoxine Irbesartan B Diphenhydramine Hcl Iron III Hydroxide Polymaltose C Betamethasone Docusate Sodium Itopride Hcl Bisacodyl Domperidone Itraconazole Bisoprolol Fumarate Doxylamine K Bromazepam CEP Donepezil Ketoconazole Bromhexine Hcl Duloxetine Ketamine Hydrochloride CEP Brompheniramine Maleate CEP Dutasteride Ketotifene Buprenorphine Hcl E Ketoprofen Bupropion Hcl Enalapril Maleate Ketorolac Tromethamine C Enrofloxacin L Calcitonine Entacapone Lamivudine Candesartan Cilexetil CEP Entecavir Monohydrate Lamotrigine Carbimazole CEP Erdostein Lansoprazole Carbocystein CEP Ertapenem Leflunomide Carvedilol Escitalopram Oxalate Letrozole Cefaclor Esomeprazole Levetiracetam Cefixime CEP F Levocetirizine Celecoxib CEP Famotidine Levofloxacin Hemihydrate Cephalexine Fenofibrate CEP Levomepromazine maleate / Hcl Cetirizine diHcl Fentanyl Citrate Levosulpiride Chlorphenesin Carbamate Fexofenadine Lidocaine Base Chlorpheniramine Maleate CEP Fluconazole CEP Lisinopril Cholecalciferol Fluoxetine CEP Loperamide Chlorpromazine Flurbiprofen Loratadine CEP Folic acid Our partners: Furosemide CEP Masenz Danya Group SL +34 933 484 605 Narcís Monturiol 37, 08960 Barcelona, www.masenzgroup.com 3 Pholcodine CEP Pioglitazone Piperaquine Phosphate Prazosin API Pregabalin Prochlorperazine Maleate Proprandol Pyridoxine Trimetoprime CEP R Triptorelin Losartan CEP Rabeprazole V Lymecycline Raloxifene Valsartan M Ramipril CEP Venlafaxine Mebendazole Ranitidine CEP Vitamine A Mebeverine Hcl Rasagiline Mesylate Vitamine B Meloxicam Rifaximin Vitamine D3 Metformin CEP Risperidone CEP Vitamine K Methylcobalamine Rivastigmine Z Metocopramide Rizatriptan Benzoate Zidovudine Metoprolol Ropinirole Zoledronic Acid Metronidazole Rosglitazone Zolmitriptan Mepyramine meleate CEP Rosuvastatin Calcium Zolpidem Tartrate Mirtazapine S Mizolastine Salbutamol CEP Montelukast Sodium CEP Veterinary APIs Sertraline Amprolium hcl N Sibutramine Bacitracin Zinc Naproxen sodium Sildenafil Nebivolol Simvastatin CEP Chlortetracycline HCL Nicardipine Sitagliptin Ciprofloxacin Hcl Nifedipine Somatostatine Colistin Sulphate Nifuroxazide Spironolactone Dexamethasone Sodium Phosphate Nimesulide Stavudine Dihydrostreptomycin Sulphate O Sulfametoxazol CEP Doxycycline Hcl Ofloxacin Sulpiride Olanzapine Enrofloxacin Base Sumatriptan succinate Florfenicol Omeoprazole CEP T Gentamycin Sulphate Ondansetron Hcl Tacrolimus Orlistat Tadalafil Ivermectin Oseltamivir Phosphate Tamoxifene Kanamycin Sulfate Oxybutynin Tamsulosine Levamisole Hcl Oxytocin Telmisartan Lincomycin Hcl P Terbutaline Sulphate Neomycin Sulphate Paracetamol CEP Theobromine CEP Oxytetracycline Base/Hcl Pantoprazole Thiamine Paroxetine CEP Progesterone Tiomolol Maleate Spectinomycin Hcl/Sulphate Penciclovir Ticlopidine Pentoxifylline Tinidazole Streptomycin Sulphate Perindorpil Erbumine Tizanidine Sulphadoxine Pheniramine Maleate CEP Tolperisone Tetracyline hydrochloride phenobarbital Topiramate Trimethoprim Phenylephirine Hcl Tramadol Tylosin Tartrate Phenytoine Triclosan Our partners: Trimebutine Masenz Danya Group SL +34 933 484 605 Narcís Monturiol 37, 08960 Barcelona, www.masenzgroup.com 4 PELLETS IMMEDIATE RELEASE PELLETS SUSTAINED RELEASE PELLETS EXTENDED RELEASE PELLETS Alphalipoic Ambroxol Ambroxol Aprepitant Ascorbic Acid Diclofenac Potassium Ascorbic Acid Chlorpheniramine Maleate Diclofenac Sodium Atorvastatin Diclofenac Potassium Diltiazem Hcl Bromhexine Diclofenac Sodium Domperidone Caffeine Hydrate Diltiazem Hcl Fenofibrate Carbonyl Iron Domperidone Itorpide Hcl Cetirizine Dried Ferrous Sulphate Ketoprofen Chlorpheniramine Maleate Ferrous Fumarate Mebeverine Ciprofloxacin Fluoxetine Mesalamine Copidogril Bisulphate Indomethacin Metroprolol Succnate Cyanocobalamiin Isosorbide Dinitrate Pseudoephedrine Dabigatran Itopride Tamsulosine Domperidone Ketoprofen Theophylline Dried Ferrous Sulphate Levosulpiride Venlafaxine Dutasteride Mebeverine Venlawafine Esomeprazole Metoprolol Succinate Folic Acid Mycophenolate Mofetil Itraconazole Nifedipine Lansoprazole Orlistat Mebeverine Phenylephrine Methyl Cobalamine Propanolol Mycophenolate Mofetil Salbutamol Sulphate Omeprazole Tacrolimus Orlistat Tamsulosin Pantoprazole Sodium Theophylline Phenylephrine Tizanidine Pyridoxine Tolterodine Rabeprazole Sodium Tramadol Riboflavine Trimetazidine Salbutamol Venlafaxine Thiamine Mononitrate Verapamil Zinc Sulphate Zinc Sulphate API DMF & PELLETS DMF Available Our partners: PHARMACEUTICALS PVT LTD Masenz Danya Group SL +34 933 484 605 Narcís Monturiol 37, 08960 Barcelona, www.masenzgroup.com 5 PREMIX A G R Aceclofenac sodium Gabapentin Risperidone Acetylsalicylic acid Amitriptyline H S Amlodipine besylate Ibuprofen Sertraline Aripiprazole Irbesartan Sildenafil citrate Sodium Valproate B M Betahistine Metformin T Bisoprolol Metoprolol Tadalafil Mirtazapine Topiramate C Montelukast Sodium Tramadol HCl Citalopram Clopidogrel N V Clozapine Naproxen Sodium Valsartan Ciprofloxacine O Z E Olanzapine Zolpidem Escitalopram Oxalate P F Paracetamol Fluoxetine HCl Paracetamol and Caffeine Phenytoin sodium Prednisolone Propranolol API DMF & PREMIX DMF Available Masenz Danya Group SL +34 933 484 605 Narcís Monturiol 37, 08960 Barcelona, www.masenzgroup.com 6 EXIPIENTS A L S Acetic Acid Lactic Acid Saccharin Sodium Aspartame Lactose monohydrate Sodium Alginate Lactose Monohydrate and Povidone Sodium Benzoate C (Ludipress ®) Sodium Bicarbonate Carbomer Sodium Citrate Dihydrate Carboxymethylcellulose Sodium M Sodium Chloride Citric Acid Monohydrate Magnesium Stearate Sodium Formaldehyde Sulfoxylate Cyclodextrins Malic Acid Sodium hydroxide Colloidal Silicone Dioxide Maltitol Solution Sodium LaurylSulfate Croscarmellose Sodium Crospovidone Maltodextrin Sodium Phosphate, Dibasic Cyclamate Mannitol Sodium Starch Glycolate Menthol Sodium Stearyl Fumarate F Methacrylic Acid Sorbitol (Liquid 70 % and powder) Flavour: Liquid and powder Methylcellulose Soya Bean Lecithin Starch Various Methylparaben Starch, Soluble and Pregelatinized Microcrystalline Cellulose Sucrose G Mineral Oil (Paraffin Liquid) Glycerin T Guar Gum P Talc Polysorbate 80 H Potassium Citrate X Hydroxyethyl Cellulose Potassium Sorbate Xanthan gum Hydroxypropyl Cellulose Povidone (k30 y k90) Low-substituted Hypromellose Propylene Glycol Propylparaben Propylparaben Sodium Prosolv ® EASYtab Our partners: We create chemistry Masenz Danya Group SL +34 933 484 605 Narcís Monturiol 37, 08960 Barcelona, www.masenzgroup.com 7 FORMULATION DOSSIERS Solid Form Injectable Form Ambroxol 30mg Adrenaline inj 1 mg / 1 ml Amlodipine + Valsartan 5 mg Amoxicillin + Clavulanate Potassium 500mg/100mg Amoxicillin + Clavulanate Potassium 250mg/125mg Amphotericin B 50mg Ampicillin + Cloxaciilin Sodium 250mg/250mg Gentamycin injectable 10 mg /ml Atenolol tablets 25 and 100 mg Ketamine injectable 50 mg / 5ml Candesartan cilexetil 4 mg , 8 mg 16 mg and 32 mg Paracetamol inj 10 mg /ml Celecoxib capsules 100 and 200 mg Ondansetron 4mg, 8mg/ 2mg Cetirizine tablets 10 mg Ranitidine injectable 50 mg / 2 ml Cetirizine + Ambroxol 5mg/60mg Cetirizine + Pseudoephedrine HCl 5mg/120mg Ophtalmic line Ciprofloxacin tablets 500 mg Colchicine tablets 1 mg Antazoline/ Naphazoline collyre 5mg/0.25mg/ml Enalapril 10 and 20 mg Atropine collyre %0.5 and 1 % Fluconazole 50mg, 200mg, 150mg Betamethasone sodium phosphate collyre 1 mg/ml Fluoxetine 2mg Ciprofloxacine collyre %0.3 Gabapentine 100 and 300 mg Gentamycine collyre 3 mg/ ml Glibenclamide 2.5mg, 5mg Neomycine collyre %1 Gliclazide 80mg Pilocarpine collyre %1 Loperamide tablets 2 mg Rifamycine collyre 1M/100ml Levofloxacin 250mg, 500mg, 750mg Levocetirizine diHCl 5mg,10mg Syrup Form Metformin + Gliclazide 500mg/80mg Metformin + Glimepiride 500mg/1mg Amoxicillin 125mg, 250mg Metformin + Glipizide 500mg + 5mg Amoxicillin + Clavulanate Potassium 125mg + Metformin HCl 500mg, 850mg, 1 gm 31.25mg, 200mg + 31.25mg, 250mg + 62.5mg Metformin HCl + Glibenclamide 500mg/5mg Levocetirizine HCl 2.5mg Metformin HCl ER 500mg, 1000mg Metformin HCl SR 850mg Cream Form Metronidazole tablets 500
Load more

Recommended publications
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Efficacy of Different Types of Therapy for COVID-19
    life Review Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review Anna Starshinova 1,*, Anna Malkova 2 , Ulia Zinchenko 3 , Dmitry Kudlay 4,5 , Anzhela Glushkova 6, Irina Dovgalyk 3, Piotr Yablonskiy 2,3 and Yehuda Shoenfeld 2,7,8 1 Almazov National Medical Research Centre, Head of the Research Department, 2 Akkuratov Str., 197341 Saint-Petersburg, Russia 2 Medical Department, Saint Petersburg State University, 199034 Saint-Petersburg, Russia; [email protected] (A.M.); [email protected] (P.Y.); [email protected] (Y.S.) 3 St. Petersburg Research Institute of Phthisiopulmonology, 199034 Saint-Petersburg, Russia; [email protected] (U.Z.); [email protected] (I.D.) 4 NRC Institute of Immunology FMBA of Russia, 115478 Moscow, Russia; [email protected] 5 Medical Department, I.M. Sechenov First Moscow State Medical University, 119435 Moscow, Russia 6 V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology, 192019 Saint Petersburg, Russia; [email protected] 7 Ariel University, Kiryat HaMada 3, Ariel 40700, Israel 8 Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer 5265601, Israel * Correspondence: [email protected]; Tel.: +7-9052043861 Citation: Starshinova, A.; Malkova, Abstract: A new coronavirus disease (COVID-19) has already affected millions of people in 213 coun- A.; Zinchenko, U.; Kudlay, D.; tries. The possibilities of treatment have been reviewed in recent publications but there are many Glushkova, A.; Dovgalyk, I.; controversial results and conclusions. An analysis of the studies did not reveal a difference in Yablonskiy, P.; Shoenfeld, Y. Efficacy mortality level between people treated with standard therapy, such as antiviral drugs and dexam- of Different Types of Therapy for ethasone, and new antiviral drugs/additional immune therapy.
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • The Action of Chlorphenesin Carbamate on the Frog Spinal Cord
    Japan. J. Pharmacol. 30, 29-36 (1980) 29 THE ACTION OF CHLORPHENESIN CARBAMATE ON THE FROG SPINAL CORD Hironaka AIHARA, Michio KURACHI, Sadao NAKANE, Michitada SASAJIMA and Masahiro OHZEKI Research Laboratories, Taisho Pharmaceutical Co., Ltd., Yoshino-cho1-403, Omiya, Saitama 330, Japan Accepted September 10, 1979 Abstract-Studies were carried out to elucidate the mechanism of action of chlor- phenesin carbamate (CPC) and to compare the effect of the drug with that of mephenesin on the isolated bullfrog spinal cord. Ventral and dorsal root potentials were recorded by means of the sucrose-gap method. CPC caused marked hyperpolarizations and depressed spontaneous activities in both of the primary afferent terminals (PAT) and motoneurons (MN). These hyperpolarizations were observed even in high-Mg" and Ca2+-freeRinger's solution, suggesting that CPC has direct actions on PAT and MN. Various reflex potentials (dorsal and ventral root potentials elicited by stimulating dorsal and ventral root, respectively) tended to be depressed by CPC as well as by mephenesin. Excitatory amino acids (L-aspartic acid and L-glutamic acid) caused marked depolarizations in PAT and MN, and increased the firing rate in MN. CPC did not modify the depolarization but abolished the motoneuron firing induced by these amino acids. However, mephenesin reduced both the depolarization and the motoneuron firing. The dorsal and ventral root potentials evoked by tetanic stimu- lation (40 Hz) of the dorsal root were depressed by the drugs. These results indicate that CPC has an apparent depressing action on the spinal neuron, and this action may be ascribed to the slight hyperpolarization and/or the prolongation of refractory period.
    [Show full text]
  • Tariff Schedule of Canada
    Tariff Schedule of Canada Tariff Item Description of Goods Base Rate Staging Category 0101.10.00 Pure-bred breeding animals Free A 0101.90.00 Other Free A 0102.10.00 Pure-bred breeding animals Free A 0102.90.00 Other Free A 0103.10.00 Pure-bred breeding animals Free A 0103.91.00 Weighing less than 50 kg Free A 0103.92.00 Weighing 50 kg or more Free A 0104.10.00 Sheep Free A 0104.20.00 Goats Free A 0105.11.10 For breeding purposes Free A 0105.11.21 Broilers for domestic production: Within access 0.86¢ each A commitment 0105.11.22 Broilers for domestic production: Over access 238% but not less E commitment than 30.8¢ each 0105.11.90 Other Free A 0105.12.10 For breeding purposes Free A 0105.12.90 Other 8% A 0105.19.10 For breeding purposes Free A 0105.19.92 Other: Guinea fowls 2.5% A 0105.19.93 Other: Ducks and geese 8% A 0105.94.10 For breeding purposes; 2.82¢/kg A Spent fowl; Started pullets 0105.94.91 Other: Within access commitment 1.90¢/kg C 0105.94.92 Other: Over access commitment 238% but not less E than $1.25/kg 0105.99.11 Turkeys: Within access commitment 1.90¢/kg C 0105.99.12 Turkeys: Over access commitment 154.5% but not less E than $1.60/kg 0105.99.90 Other 3% A 0106.11.00 Primates Free A 0106.12.00 Whales, dolphins and porpoises (mammals of the order Free A Cetacea); manatees and dugongs (mammals of the order Sirenia) 0106.19.00 Other Free A 0106.20.00 Reptiles (including snakes and turtles) Free A 0106.31.00 Birds of prey Free A 0106.32.00 Psittaciformes (including parrots, parakeets, macaws and Free A cockatoos) 0106.39.00
    [Show full text]
  • II.4.6 Muscle Relaxants by Mayumi Nishikawa and Hitoshi Tsuchihashi
    4.6 II.4.6 Muscle relaxants by Mayumi Nishikawa and Hitoshi Tsuchihashi Introduction Muscle relaxants can be classifi ed into the peripheral-and central-acting drug types (> Table 6.1). Th e drugs of the peripheral type are also called neuromuscular blocking agents. Th e peripheral- acting muscle relaxants are being used for muscle relaxation upon endotracheal intubation and/or general anaesthesia for surgical operation. Th e central-acting muscle relaxants are used for treat- ments of painful muscle contracture caused by locomotorial disorders, and for relaxation of mus- cle stiff ness caused by psychotic tension or by neurosis. Th e cases of poisoning by the peripheral- acting muscle relaxants oft en take place, because of its strong suppressive action on respiration. However, their poisoning is rare at the scene of medical treatments, because the risk is usually avoided by artifi cial respiration. Most of poisoning incidents due to the peripheral-acting muscle relaxants are intentional and/or homicidal. In this chapter, therefore, analytical methods only for the peripheral-acting muscle relaxants (> Table 6.2) are dealt with. Since these drugs are quater- nary ammonium salts, special care should be taken for their stability and effi cient extraction [1]. TLC analysis Reagents and its preparation • Tubocurarine chloride, suxamethonium chloride ( succinylcholine chloride) and pan- curonium bromide can be purchased from Sigma (St. Louis, MO, USA). For vecuronium bromide, pure powder is not commercially available; ampoule solution for
    [Show full text]
  • Supplement I to JP XV
    The Ministry of Health, Labour and Welfare Ministerial Notification No. 316 Pursuant to Paragraph 1, Article 41 of the Pharmaceutical AŠairs Law (Law No. 145, 1960), we hereby revise a part of the Japanese Pharmacopoeia (Ministerial Notiˆcation No. 285, 2006) as follows*, and the revised Japanese Pharmacopoeia shall come into eŠect on October 1, 2007. However, in the case of drugs which are listed in the Japanese Pharmacopoeia (hereinafter referred to as ``previous Phar- macopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notiˆcation (hereinafter referred to as ``new Pharmacopoeia'')] and drugs which have been approved as of October 1, 2007 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare speciˆes (the Ministry of Health and Welfare Ministerial Notiˆcation No. 104, 1994) as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Pharmaceutical AŠairs Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards estab- lished in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards estab- lished in the new Pharmacopoeia before and on March 31, 2009. In the case of drugs which are listed in the new Pharmacopoeia (excluding those listed in the previous Pharmacopoeia) and drugs which have been approved as of October 1, 2007 as prescribed under Paragraph 1, Article 14 of the same law (including those exempted from approval), they may be accepted as those being not listed in the new Phar- macopoeia before and on March 31, 2009.
    [Show full text]
  • Title 21 Food and Drugs Parts 500 to 599
    Title 21 Food and Drugs Parts 500 to 599 Revised as of April 1, 2018 Containing a codification of documents of general applicability and future effect As of April 1, 2018 Published by the Office of the Federal Register National Archives and Records Administration as a Special Edition of the Federal Register VerDate Sep<11>2014 18:00 Apr 30, 2018 Jkt 244075 PO 00000 Frm 00001 Fmt 8091 Sfmt 8091 Q:\21\ARCHIVE\21V6.TXT 31 kpayne on DSK54DXVN1OFR with $$_JOB U.S. GOVERNMENT OFFICIAL EDITION NOTICE Legal Status and Use of Seals and Logos The seal of the National Archives and Records Administration (NARA) authenticates the Code of Federal Regulations (CFR) as the official codification of Federal regulations established under the Federal Register Act. Under the provisions of 44 U.S.C. 1507, the contents of the CFR, a special edition of the Federal Register, shall be judicially noticed. The CFR is prima facie evidence of the origi- nal documents published in the Federal Register (44 U.S.C. 1510). It is prohibited to use NARA’s official seal and the stylized Code of Federal Regulations logo on any republication of this material without the express, written permission of the Archivist of the United States or the Archivist’s designee. Any person using NARA’s official seals and logos in a manner inconsistent with the provisions of 36 CFR part 1200 is subject to the penalties specified in 18 U.S.C. 506, 701, and 1017. Use of ISBN Prefix This is the Official U.S. Government edition of this publication and is herein identified to certify its authenticity.
    [Show full text]
  • 153 Part 520—Oral Dosage Form New Animal Drugs
    Food and Drug Administration, HHS Pt. 520 PART 520—ORAL DOSAGE FORM 520.420 Chlorothiazide tablets and boluses. 520.434 Chlorphenesin carbamate tablets. NEW ANIMAL DRUGS 520.441 Chlortetracycline powder. 520.443 Chlortetracycline tablets and Sec. boluses. 520.23 Acepromazine. 520.445 Chlortetracycline and 520.28 Acetazolamide. sulfamethazine powder. 520.38 Albendazole oral dosage forms. 520.446 Clindamycin capsules and tablets. 520.38a Albendazole suspension. 520.447 Clindamycin solution. 520.38b Albendazole paste. 520.452 Clenbuterol syrup. 520.43 Afoxolaner. 520.455 Clomipramine tablets. 520.48 Altrenogest. 520.462 Clorsulon drench. 520.62 Aminopentamide. 520.522 Cyclosporine. 520.82 Aminopropazine oral dosage forms. 520.530 Cythioate oral liquid. 520.82a Aminopropazine. 520.531 Cythioate tablets. 520.82b Aminopropazine and neomycin. 520.534 Decoquinate. 520.88 Amoxicillin oral dosage forms. 520.538 Deracoxib. 520.88a Amoxicillin trihydrate film-coated 520.540 Dexamethasone oral dosage forms. tablets. 520.540a Dexamethasone powder. 520.88b Amoxicillin trihydrate for oral sus- 520.540b Dexamethasone tablets and pension. boluses. 520.88c Amoxicillin trihydrate oral suspen- 520.540c Dexamethasone chewable tablets. sion. 520.563 Dexamethasone chewable tablets. 520.88d Amoxicillin trihydrate soluble pow- 520.580 Dichlorophene and toluene. der. 520.581 Dichlorophene tablets. 520.88e Amoxicillin trihydrate boluses. 520.600 Dichlorvos. 520.88f Amoxicillin trihydrate tablets. 520.606 Diclazuril. 520.88g Amoxicillin trihydrate and 520.608 Dicloxacillin. clavulanate potassium film-coated tab- 520.620 Diethylcarbamazine oral dosage lets. forms. 520.88h Amoxicillin trihydrate and 520.622 Diethylcarbamazine citrate oral dos- clavulanate potassium for oral suspen- age forms. sion. 520.622a Diethylcarbamazine citrate tablets. 520.90 Ampicillin oral dosage forms.
    [Show full text]
  • Repurposing of Approved Drugs from the Human Pharmacopoeia to Target Wolbachia Endosymbionts of Onchocerciasis and Lymphatic filariasis
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector International Journal for Parasitology: Drugs and Drug Resistance 4 (2014) 278–286 Contents lists available at ScienceDirect International Journal for Parasitology: Drugs and Drug Resistance journal homepage: www.elsevier.com/locate/ijpddr Repurposing of approved drugs from the human pharmacopoeia to target Wolbachia endosymbionts of onchocerciasis and lymphatic filariasis Kelly L. Johnston a,1, Louise Ford a,1, Indira Umareddy b,1, Simon Townson c, Sabine Specht d, ⇑ Kenneth Pfarr d, Achim Hoerauf d, Ralf Altmeyer b,e, Mark J. Taylor a, a Filariasis Research Group, Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK b CombinatoRx-Singapore Ptd Ltd, 11 Biopolis Way, 138667 Singapore, Singapore c Tropical Parasitic Diseases Unit, Northwick Park Institute for Medical Research, Watford Road, Harrow, Middlesex HA1 3UJ, UK d Institute of Medical Microbiology, Immunology & Parasitology, University Hospital of Bonn, Sigmund Freud Strasse 25, 53105 Bonn, Germany e Institut Pasteur Shanghai, Chinese Academy of Sciences, 320 Yueyang Road, 200031 Shanghai, People’s Republic of China article info abstract Article history: Lymphatic filariasis and onchocerciasis are debilitating diseases caused by parasitic filarial nematodes Available online 16 September 2014 infecting around 150 million people throughout the tropics with more than 1.5 billion at risk. As with other neglected tropical diseases, classical drug-discovery and development is lacking and a 50 year Keywords: programme of macrofilaricidal discovery failed to deliver a drug which can be used as a public health tool. Wolbachia Recently, antibiotic targeting of filarial Wolbachia, an essential bacterial symbiont, has provided a novel Filariasis drug treatment for filariasis with macrofilaricidal activity, although the current gold-standard, doxycy- Pharmacopoeia cline, is unsuitable for use in mass drug administration (MDA).
    [Show full text]
  • The Japanese Pharmacopoeia Fifteenth Edition Shall Be Partially Amended As Follows：
    Description of content： The Japanese Pharmacopoeia Fifteenth edition shall be partially amended as follows： １．To amend 1 article under the section of General Notice（List 1） ２．To amend 1 article under the section of General Rules for Crude Drugs（List 2） ３．To amend 5 articles under the section of General Rules for Preparations（List 3） ４．To establish 1 test method under the section of General Tests, Process and Apparatus （List 4） ５．To amend 9 test methods under the section of General Tests, Process and Apparatus（List 5） ６．To delete 6 monographs under the section of Monographs（List 6） ７．To establish 90 monographs under the section of Monographs（List 7） ８．To amend 171 monographs under the section of Monographs（List 8） List 1 9 List 2 1 List 3 （1）Extracts （2）Ophthalmic Ointments （3）Tinctures （4）Ophthalmic Solutions （5）Fluidextracts List 4 （1）Foreign Insoluble Matter Test for Ophthalmic Solutions List 5 （1）Qualitative Tests （2）Liquid Chromatography （3）Gas Chromatography （4）Water Determination （5）Optical Rotation Determination （6）Microbial Limit Test （7）Test for Metal Particles in Ophthalmic Ointments （8）Insoluble Particulate Matter Test for Injections （9）Dissolution Test List 6 （1）Sulfinpyrazone （2）Sulfinpyrazone Tablets （3）Tubocurarine Chloride Hydrochloride Hydrate （4）Tubocurarine Chloride Hydrochloride Injection （5）Fosfestrol （6）Fosfestrol Tablets List 7 （1）Aztreonam for Injection （2）Acemetacin （3）Azelastine Hydrochloride （4）Amikacin Sulfate Injection （5）Amlodipine Besilate （6）Amosulalol Hydrochloride （7）Amosulalol Hydrochloride Tablets （8）Alprostadil
    [Show full text]